HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.

AbstractBACKGROUND/AIMS:
Prostate cancer (PCa) is one of the most common malignant cancers and a major leading cause of cancer deaths in men. Cancer stem-like cells are shown to be highly tumorigenic, pro-angiogenic and can significantly contribute to tumor new vessel formation and bone marrow derived-EPCs (BM-EPCs) are shown to recruit to the angiogenic switch in tumor growth and metastatic progression, suggesting the importance of targeting cancer stem cells (CSCs) and EPCs for novel tumor therapies. Pristimerin, an active component isolated from Celastraceae and Hippocrateaceae, has shown anti-tumor effects in some cell lines in previous studies. However, the effect and mechanism of Pristimerin on CSCs and EPCs in PCa bone metastasis are not well studied.
METHODS:
The effect of Pristimerin on PC-3 stem cell characteristics and metastasis were detected by spheroid formation, CD133 and CD44 protein expression, matrix-gel invasive assay and colony-formation assay in vitro, VEGF and pro-inflammatory cytokines expression by ELISA assay, and tumor tumorigenicity by X-ray and MR in NOD-SCID mice model in vivo. In addition, we also detected the effect of Pristimerin on VEGF-induced vasculogenesis and protein expression of BM-EPCs.
RESULTS:
Pristimerin could significantly inhibit spheroid formation and protein expression of CD133 and CD44, reduce VEGF and pro-inflammation cytokines expression of PC-3 cell, and prevent the xenografted PC-3 tumor growth in the bone of nude mice. The present data also showed that Pristimerin significantly inhibited VEGF-induced vasculogenesis of BM-EPCs by suppressing the EPCs functions including proliferation, adhesion, migration, tube formation and inactivation the phosphorylation of VEGFR-2, Akt and eNOS.
CONCLUSION:
These data provide evidence that Pristimerin has strong potential for development as a novel agent against prostate bone metastasis by suppressing PC-3 stem cell characteristics and VEGF-induced vasculogenesis of BM-EPCs.
AuthorsShuai Huang, Peiheng He, Xinsheng Peng, Jinglei Li, Dongliang Xu, Yubo Tang
JournalCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology (Cell Physiol Biochem) Vol. 37 Issue 1 Pg. 253-68 ( 2015) ISSN: 1421-9778 [Electronic] Germany
PMID26302893 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 S. Karger AG, Basel.
Chemical References
  • AC133 Antigen
  • Antigens, CD
  • Glycoproteins
  • Hyaluronan Receptors
  • PROM1 protein, human
  • Pentacyclic Triterpenes
  • Peptides
  • Prom1 protein, mouse
  • Triterpenes
  • Vascular Endothelial Growth Factor A
  • Nitric Oxide Synthase Type III
  • Vascular Endothelial Growth Factor Receptor-2
  • Proto-Oncogene Proteins c-akt
  • celastrol
Topics
  • AC133 Antigen
  • Aged
  • Animals
  • Antigens, CD (metabolism)
  • Bone Marrow Cells (drug effects, metabolism, pathology)
  • Bone Neoplasms (metabolism, pathology, prevention & control)
  • Cell Line, Tumor
  • Endothelial Cells (drug effects, metabolism)
  • Glycoproteins (metabolism)
  • Humans
  • Hyaluronan Receptors (metabolism)
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, Nude
  • Mice, SCID
  • Middle Aged
  • Neoplastic Stem Cells (drug effects, metabolism, pathology)
  • Neovascularization, Pathologic (drug therapy, metabolism, pathology)
  • Nitric Oxide Synthase Type III (metabolism)
  • Pentacyclic Triterpenes
  • Peptides (metabolism)
  • Prostatic Neoplasms (drug therapy, metabolism, pathology)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Triterpenes (pharmacology)
  • Vascular Endothelial Growth Factor A (metabolism)
  • Vascular Endothelial Growth Factor Receptor-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: